ANTI-LEUKOCYTE ADHESION FOR THE MITIGATION OF POTENTIAL ADVERSE EVENTS CAUSED BY CD3-SPECIFIC BINDING DOMAINS
摘要
<p>The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.</p>